Location History:
- Tampa, FL (US) (2010)
- Temple Terrace, FL (US) (2010)
- La Jolla, CA (US) (2011 - 2021)
Company Filing History:
4 out of 1,187 
4 out of 1,935 
3 out of 48 Years Active: 2010-2021
Title: Caroline Desponts: Innovator in Cell Therapy
Introduction
Caroline Desponts is an accomplished inventor based in La Jolla, California. With a strong focus on cell therapy, she has contributed significantly to the field through her innovative work and numerous patents. Her expertise lies in enhancing the efficacy of hematopoietic stem and progenitor cells, paving the way for advanced therapeutic applications.
Latest Patents
Among her impressive portfolio, Caroline holds 11 patents, one of the most notable being the "Enhanced Stem Cell Composition." This patent outlines improved methods for cell therapy, presenting therapeutic compositions of enhanced hematopoietic stem and progenitor cells with superior engraftment and homing properties. The invention also includes methods for increasing the success of hematopoietic stem and progenitor cell transplantation, particularly for patients needing reconstitution of their hematopoietic system.
Career Highlights
Caroline has worked with prestigious institutions, including The Scripps Research Institute and the University of South Florida. Her experience in these research settings has played a pivotal role in her discoveries, leading to advancements in cell therapy techniques and applications.
Collaborations
Throughout her career, Caroline has collaborated with notable colleagues such as Yan Shi and Sheng Ding. These partnerships have allowed her to expand her research's scope and impact, contributing to the growth and development of her innovative ideas.
Conclusion
Caroline Desponts exemplifies a passionate inventor dedicated to advancing medical science through her innovations in cell therapy. With her array of patents and collaborations with esteemed institutions and colleagues, she continues to push the boundaries of what is possible in the field. As she moves forward, her contributions will undoubtedly lead to new possibilities in therapeutic applications for hematopoietic stem cell research.